Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced it will report financial results for Q1 2022, ending March 31, after market close on May 12, 2022. A conference call will take place at 4:30 p.m. ET on the same day, accessible via phone or webcast. The company's focus is on developing treatments for serious diseases, with lead candidate VRDN-001 targeting insulin-like growth factor-1 receptor for thyroid eye disease, and VRDN-002, an extended half-life anti-IGF-1R antibody for convenient subcutaneous administration.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will participate in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, starting at 4:30 p.m. ET. The conference will feature a corporate overview presentation. A live webcast and replay are available on Viridian's investor relations website.

Viridian focuses on innovative treatments for serious diseases, with its leading candidate, VRDN-001, targeting insulin-like growth factor-1 receptor for thyroid eye disease. The second candidate, VRDN-002, is designed for convenient subcutaneous administration.

Viridian Therapeutics (NASDAQ: VRDN) has secured a debt financing agreement with Hercules Capital for up to $75 million. The initial drawdown of $5 million has been completed, with additional funds contingent on milestones and lender approval. As of December 31, 2021, Viridian reported a cash position exceeding $197 million, expected to fund operations through 2024, excluding this new facility. The financing aims to enhance the company's operational flexibility while advancing clinical programs VRDN-001 and VRDN-002, targeting thyroid eye disease.

Viridian Therapeutics has initiated a Phase 1 clinical trial for VRDN-002, a monoclonal antibody designed to treat thyroid eye disease (TED). This trial involves 16 healthy volunteers receiving ascending doses of VRDN-002 to assess its safety and efficacy as a low-volume subcutaneous injection. Results are anticipated mid-year. This milestone supports Viridian's strategy to enhance patient care for TED, potentially allowing for at-home self-administration or treatment in a physician's office.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm focused on treating serious diseases, will have its CEO, Jonathan Violin, participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 10:40 a.m. ET. This event highlights the company's efforts to advance new therapies, particularly VRDN-001, a monoclonal antibody for thyroid eye disease, and VRDN-002, a half-life extended treatment option. Interested parties can view the live webcast and replay on Viridian's website.

Viridian Therapeutics (NASDAQ: VRDN) reported financial results for Q4 and FY 2021, highlighting a strong cash position of $197 million to fund operations into 2024.

The company has two ongoing clinical trials for its IGF-1R antibodies, VRDN-001 and VRDN-002, targeting Thyroid Eye Disease (TED), with top-line data expected in Q2 and mid-2022, respectively.

Despite a net loss of $28.9 million in Q4 2021, this is an improvement from $90.7 million in the previous year, driven by reduced R&D expenses.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) will report its financial results for the fourth quarter and full year ended December 31, 2021, on March 10, 2022, after market close. The management will host a conference call at 4:30 p.m. ET on the same day. Interested parties can listen by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international) with conference ID: 13727096. The call will also be available via live webcast on the company's investor site. Viridian focuses on developing treatments for serious diseases, targeting insulin-like growth factor-1 receptor for thyroid eye disease.

Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18 at 2:20 PM ET. The event aims to discuss advancements in treatments for serious diseases, focusing on their lead product, VRDN-001, targeting thyroid eye disease (TED). This condition can cause severe complications, necessitating surgical interventions. A live webcast and replay of the chat will be available on Viridian's website.

Viridian Therapeutics has received FDA clearance for its investigational new drug application for VRDN-002, a novel monoclonal antibody using half-life extension technology. The VRDN-002 is designed for low-volume subcutaneous injection to treat thyroid eye disease (TED). The company plans to initiate a first-in-human Phase 1 clinical trial to assess safety and pharmacokinetics, with results expected in mid-2022. This marks a key developmental milestone as Viridian aims to enhance treatment convenience for TED patients.